Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00087789 · ClinicalTrials.gov registry record · Phase 1

CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease

A Phase 1 study of Alzheimers Disease, sponsored by Sangamo Therapeutics.

Completed
Registry status
Phase 1
Development phase
10
Enrollment target
2
Study locations

NCT00087789 is a Phase 1 study of Alzheimers Disease that has completed, run by Sangamo Therapeutics. The registered enrollment target is 10 participants, below the 4,061-participant average among 142 other Alzheimers Disease trials with a reported enrollment target (100% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00087789, a Phase 1 study of Alzheimers Disease, has completed, sponsored by Sangamo Therapeutics.

COMPLETED
Registry status
Phase 1
Development phase
10 participants
Enrollment target
2
Study locations

Study Summary

This is a Phase I clinical study to assess the safety, tolerability and biologic activity of in vivo AAV-mediated delivery of CERE-110. Up to 12 subjects will receive open label CERE-110 in dose-escalating fashion. All subjects will receive bilateral, stereotactic injections of CERE-110 for a total of four (Dose A and B) and six (Dose C) injections to target the basal forebrain region of the brain containing the nucleus basalis of Meynert (NBM). All study participants will be observed for a 24-month period and then followed annually.

Conditions Studied

Alzheimers Disease

Interventions

  • GENETIC CERE-110: Adeno-Associated Virus Delivery of NGF

Study Locations (2)

California

  • University of California San Diego - San Diego

Illinois

  • Rush University Medical Center - Chicago

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2004-06
Est. Completion 2010-05
Phase Phase 1

Sponsor

Sangamo Therapeutics

25 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00087789

The ClinicalTrials.gov registry entry for NCT00087789 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,061-participant average among 142 other Alzheimers Disease trials with a reported enrollment target (100% lower). The listed sponsor is Sangamo Therapeutics, which has 25 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Alzheimers Disease appearing as the primary indexed condition, and to 1 intervention - of which CERE-110: Adeno-Associated Virus Delivery of NGF is the first listed.

NCT00087789 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, Illinois.

Frequently Asked Questions

What is clinical trial NCT00087789 about?

NCT00087789 is a clinical study titled "CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease". This is a Phase I clinical study to assess the safety, tolerability and biologic activity of in vivo AAV-mediated delivery of CERE-110. Up to 12 subjects will receive open label CERE-110 in dose-escalating fashion. All subjects will receive bilateral, stereotactic injections of CERE-110 for a total ...

What is the current status of trial NCT00087789?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2004-06. Estimated completion is 2010-05.

What conditions does trial NCT00087789 study?

This clinical trial studies the following conditions: Alzheimers Disease.

What interventions are being tested in trial NCT00087789?

The interventions under investigation include: CERE-110: Adeno-Associated Virus Delivery of NGF (GENETIC).

Who is sponsoring clinical trial NCT00087789?

This trial is sponsored by Sangamo Therapeutics, which has 25 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00087789 being conducted?

This trial has 2 study locations across California, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Alzheimers Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Alzheimers Disease

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.